Skip to main content
Yuankang Feng on Muck Rack

Yuankang Feng

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yuankang

Contact Yuankang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

LD–associated signatures identified by perilipin-based proximity labeling proteomics reveal GNA14 as a therapeutic and prognostic target in renal cell carcinoma

|
By Yuankang Feng, Xinran Zhang, Shiyue Zhang, Jianqiao Li, Zhihao Bo, Jialu Ma, Xinyu Liu, Yang Liu Verified, Shumin Yu, Rui Wang, Yaqun Zhang, Dan Yue, Yong Huei Wang, Mingjian Lian
| Nature Verified
Abstract Renal cell carcinoma (RCC), especially clear cell RCC (ccRCC), is characterized by metabolic reprogramming, notably disordered lipid metabolism and prominent intracellular lipid droplet accumulation. In addition to abnormal triglyceride and cholesterol ester storage, lipid droplets promote tumor proliferation, survival, and drug resistance by supplying energy, membrane components, and signaling platforms, thereby representing potential therapeutic targets.
Open in Who Shared Issue with article?

Targeted inhibition of the CREB1-CtIP axis enhances the efficacy of abiraterone combined with radiotherapy in prostate cancer

|
By Xu Han, Yuankang Feng, Zihao Wang, Lina Wang, Ruoyang Liu, Yu Chi Liu, Ningyang Li, Saiyu Ma, Jinjian Yang, Zhenlin Huang, Zhankui Jia, Fubo Lu
| Nature Verified
Abstract In the treatment of locally advanced prostate cancer (PCa), abiraterone acetate (AA) serves both as a commonly used therapeutic agent and a radiosensitizer when combined with radiation therapy (RT). However, this combination therapy is not effective for all patients, and prolonged treatment may lead to decreased therapeutic sensitivity.
Open in Who Shared Issue with article?

PRR15 suppresses renal cell carcinoma progression via the NF-κB/FDX1 axis to induce cuproptosis and mitochondrial dysfunction - Oncogene

|
By Jialu Ma, Jianqiao Li, Shiyue Zhang, Xinyu Liu, Yihan Dong, Jiaxin Li, Shaomin Guo, Rui Wang, Dan Yue, Yong Huei Wang, Zhihao Bo, Yuankang Feng, Yuejing Pan, Huamao Jiang
| Nature Verified
Abstract Cuproptosis is involved in the proliferation, metastasis, and drug resistance formation development of renal cell carcinoma (RCC) by regulating lipid metabolism and oxidative stress levels in the tumor microenvironment, with Ferredoxin 1 (FDX1) as a core regulator.
Open in Who Shared Issue with article?
See all 3 articles